Corbion Reports Q3 2026 Financial Results, Halts PLA Business Sale
Corbion reported strong organic sales growth in Q3, particularly in Health & Nutrition. It maintained its 2026 guidance and said proposals for its PLA business undervalued the asset.
Corbion reported its Q3 2026 financial results, highlighting strong organic sales growth driven by both its Functional Ingredients & Solutions and Health & Nutrition segments, with the latter showing particularly strong performance. Alongside the earnings report, management announced the decision to halt the sale of the company's PLA business, citing that received proposals undervalued the asset. The company also maintained its full-year 2026 financial guidance, supported by a visible order book for the fourth quarter.